Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM6A | O15550 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KDM5C | P41229 | 1/20 | 0.46 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.46 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 8/20 | 0.40 |
| ▸ | COMT | P21964 | 2/20 | 0.40 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deferiprone SCHEMBL7224598 | 0.89 | KDM4E (0.67) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL8612707 | 0.87 | KDM4E (0.46) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6998644 | 0.85 | KDM4E (0.45) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL5515462 | 0.85 | KDM4E (0.47) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL12949549 | 0.84 | KDM4E (0.42) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL8129400 | 0.84 | KDM4E (0.44) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL13555547 | 0.84 | KDM4E (0.44) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL4754379 | 0.84 | KDM4E (0.46) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL5525055 | 0.82 | KDM4E (0.62) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL9701411 | 0.82 | KDM4E (0.46) | KDM4ETP53CYP2D6HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220031738-A1 | IRON FORMULATIONS FOR TOPICAL ADMINISTRATION AND METHODS OF TREATMENT OF IRON DEFICIENCY | DYVE BIOSCIENCES, INC. (US) | 2022-02-03 | — | — | US | claimed |
| US-20180071238-A1 | Compositions and Methods for Traumatized Tissues Using Zinc Chelators | OHIO UNIVERSITY (US) | 2018-03-15 | — | — | US | claimed |
| WO-2016164685-A1 | COMPOSITIONS AND METHODS FOR TRAUMATIZED TISSUES USING ZINC CHELATORS | OHIO UNIVERSITY (US) | 2016-10-13 | — | — | WO | claimed |
| EP-2682120-B1 | Stable laquinimod preparations | TEVA PHARMA (IL) | 2016-08-03 | — | — | EP | claimed |
| EP-2682120-A1 | Stable laquinimod preparations | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2014-01-08 | — | — | EP | claimed |
| US-8545885-B2 | Stable laquinimod preparations | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2013-10-01 | — | — | US | claimed |
| EP-1567156-B1 | HYDROXYPYRIDINONES FOR THE LOCAL TREATMENT OF SKIN MICROCIRCULATORY DISORDERS | RELIVIA SRL (IT) | 2009-08-26 | — | — | EP | claimed |
| US-7160482-B2 | Composition comprising an oxidizing and complexing compound | IMEC VZW (BE) | 2007-01-09 | — | — | US | claimed |
| EP-0613560-B2 | A METHOD FOR ASSAYING AND TREATING ALZHEIMER'S DISEASE | PRANA BIOTECHNOLOGY LTD (AU) | 2006-06-21 | — | — | EP | claimed |
| US-20050009207-A1 | Composition comprising an oxidizing and complexing compound | VERSUM MATERIALS US, LLC | 2005-01-13 | — | — | US | claimed |
| US-20040265847-A1 | Method for treating Alzheimer's disease | MASTERS COLIN LOUIS | 2004-12-30 | — | — | US | claimed |
| WO-2001017497-A1 | DEPIGMENTING COMPOSITIONS | GHISALBERTI CARLO (BR) | 2001-03-15 | — | — | WO | claimed |
| EP-0613560-B1 | A METHOD FOR ASSAYING AND TREATING ALZHEIMER'S DISEASE | UNIV MELBOURNE (AU) | 1998-10-21 | — | — | EP | claimed |
| EP-0613560-A4 | A METHOD FOR ASSAYING AND TREATING ALZHEIMER'S DISEASE. | UNIV MELBOURNE (AU) | 1995-05-17 | — | — | EP | claimed |
| EP-0613560-A1 | A METHOD FOR ASSAYING AND TREATING ALZHEIMER'S DISEASE | THE UNIVERSITY OF MELBOURNE (AU) | 1994-09-07 | — | — | EP | claimed |
| EP-0397409-B1 | THE STABILIZATION OF ORGANIC COMPOUNDS | BTG INTERNATIONAL LIMITED (GB) | 1993-07-21 | — | — | EP | claimed |
| WO-1993010459-A1 | A METHOD FOR ASSAYING AND TREATING ALZHEIMER'S DISEASE | THE UNIVERSITY OF MELBOURNE (AU) | 1993-05-27 | — | — | WO | claimed |
| EP-0397409-A1 | The stabilization of organic compounds | BTG INTERNATIONAL LIMITED (GB) | 1990-11-14 | — | — | EP | claimed |
| WO-1989009211-A1 | PROCESS FOR PRODUCING PYRID-4-ONES | THE ROYAL FREE HOSPITAL SCHOOL OF MEDICINE (GB) | 1989-10-05 | — | — | WO | claimed |
| EP-0335745-A1 | Process for producing pyrid-4-ones | THE ROYAL FREE HOSPITAL SCHOOL OF MEDICINE (GB) | 1989-10-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009207-A1 | Composition comprising an oxidizing and complexing compound | C5, SCO2, NOX4 | KDM4E 2769/4885TP53 4301/4885CYP2D6 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.